Merck KGaA, headquartered in Darmstadt, Germany, is a leading global chemical and pharmaceutical company, recognized as the world's oldest in the industry, dating back to 1668. The company operates through three primary segments: life sciences, healthcare, and performance materials. Its life sciences division supplies laboratory consumables and services, accounting for 44% of sales, while the healthcare segment, contributing 38%, develops and sells branded pharmaceuticals with a focus on oncology, multiple sclerosis, and fertility. The performance materials segment, making up 17% of sales, provides specialty materials for various applications, including semiconductors and electronics. Merck also engages in consumer health, offering over-the-counter products across more than 100 countries. Additionally, Merck has established an innovation center that supports early-stage startups in healthcare and life sciences. The company maintains a significant presence in Europe, Asia, Latin America, and Africa, with a strong emphasis on collaboration and innovation in its business practices.
Eurocine Vaccines creates nasal flu vaccines designed for children and the elderly. They manage all elements of vaccine development, including preclinical and clinical development, scalability into manufacturing, business development, and funding.
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.
Formo is Europe’s first cellular agriculture company developing animal-free dairy products using real, nature-identical milk proteins derived from precision fermentation.
Akili Labs is a biomedical startup that focuses on medical diagnostic technology. They focus on developing medical diagnostic systems to improve healthcare through improved diagnostics allowing for targeted treatments. Akili Labs is a multi-award-winning biotechnology business that specializes in the creation of molecular diagnostic tools. It was started in 2017 by Charles Faul and Lucas Lotter, with Dr Farhan Pervaiz joining as a co-founder in 2018. Akili Labs, based in South Africa with international affiliations, was founded in response to the need for quick diagnoses in the healthcare system. Akili Labs consistently forges collaborations with organizations throughout the world for the development, design, and implementation of healthcare and diagnostic-related products, with innovation and collaboration at the forefront of its firm purpose.
Epilert creates wearable technology for people with neurological illnesses to support them in daily life and to provide improved, better fast access to healthcare when necessary. It employs sensors and machine learning to identify epilepsy episodes, warn carers, and track physical activity and sleep patterns.
Intermolecular provides high productivity combinatorial (HPC) technology products and services. The company offers Tempus HPC Platform, an integrated processing and informatics system that stimulates materials discovery, process development, and IC device integration for chipmakers, materials suppliers, and equipment manufacturers. It also offers wet workflow systems for self-assembly processing, electroless deposition, wet etching and stripping, cleaning, and surface preparation applications; ALD and PVD workflow systems; and HPC test chips. The company serves pharmaceutical, biotechnology, and energy industries.
Versum Materials is a the global specialty materials company providing high-purity chemicals and gases, delivery systems, services and materials expertise to meet the evolving needs of the global semiconductor and display industries. Derived from the Latin word for "toward," the name "Versum" communicates the company's deep commitment to helping customers move toward the future by collaborating, innovating and creating cutting-edge solutions.
Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.
RxAll is a Deep Learning-Hyperspectral IoT Platform for instant authentication and real-time global tracking of quality of drugs- prescription & OTC meds., opioids, recreational drugs and cannabis- through mobile phones and a cloud based platform. We deliver authenticated medicines to hospitals, pharmacies and patients.
Grzybowski Scientific Inventions
Acquisition in 2017
Grzybowski Scientific Inventions (GSI) is a start-up company with exclusive licensing, development, marketing and sales rights to the revolutionary chemistry decision-making and synthetic planning software product Chematica. Since its establishment in December 2013, GSI has successfully engaged a clientele composed of a wide range of industries as well as academic and government institutions from all over the world.
Clustermarket is the leading operating system for life-sciences laboratories. Our goal is to bring the management of research into the digital age, democratise access to expensive equipment and services and ultimately to enable life sciences innovators to get ideas to market faster than ever before. Our award-winning lab management software (previously known as Bookkit) and revolutionary marketplace helps labs to manage, connect and share resources.
Ormet Circuits, Inc. designs, manufactures, and sells conductive pastes and inks for printed circuit board fabrication and microelectronics industries. The company provides lead-free copper-based sintering pastes. Its products are applied in semiconductor packaging, die attach, printed circuit boards, photovoltaic, lead free solder replacement, and electro-magnetic shielding. Ormet Circuits, Inc. was formerly known as Toranaga Technologies, Inc. The company was incorporated in 2001 and is based in San Diego, California with distribution and representative organizations worldwide.
Qlight Nanotech develops semiconductor nanocrystals that display unique optical and electrical properties. Qlight’s nanocrystals enable light conversion from UV and blue wavelengths to any other wavelength in the visible range. The color, or the wavelength, of the light is determined by the nanoparticle's size. When excited by light, nanocrystals generate illumination of an unmatched color and wavelength accuracy while displaying high quantum efficiency. This guarantees high energy efficiency and cost savings for solid state lighting (LED) systems, flat panel displays and various other optical applications.
Sigma-Aldrich is a leading Life Science and High Technology company. Our chemical and biochemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich operates in 40 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customers' Success through Innovation and Leadership in Life Science, High Technology and Service. Sigma-Aldrich Corporation was founded in 1951.
AZ Electronic Materials S.A., through its subsidiaries, produces and supplies specialty chemical materials for the electronics market. The company operates through IC Materials, Optronics, and Printing and Other segments. Its materials are used in integrated circuits and devices, flat panel displays, light-emitting diodes, and photolithographic printing.
CellASIC is a biotechnology company that develops microfluidic platform for live cell analysis experiments by facilitating long-term perfusion cell culture. The company engineers platforms that utilize cutting edge microfluidics technology to provide superior live cell analysis with dynamic flow control. The company is founded on 2005 and is headquartered in Hayward, California.
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.
Seven Seas Ltd. provides vitamins, minerals, and supplements worldwide. It offers liver oils, health oils, jointcare products, multivitamins, skin nutrition products, pregnancy products, immune support products, cold and flu relief products, and pulse/cardiom products. The company’s products are used in various applications, such as everyday health, digestive health, exercise and sport, immunity, cold and flu relief, tiredness reduction, energy, brain health, hectic living, heart health, joint health, women's health, pregnancy nutrition, new mums, skin health, hair and nail health, menopause, children's health, teen health, 50+ health, and men's health.
Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Suzhou Taizhu Technology Development
Acquisition in 2009
Suzhou Taizhu Technology Development Co., Ltd. is manufactures and supplies effect pigments for printing, plastics, coating, and cosmetics industries.
LITEC-LLL is develops, produces, and markets custom phosphors. It offers LED phosphors for lamps, and blue and UV-LEDs, as well as phosphor mixtures. The company also produces ortho-silicate lighting materials, as well as provides lighting engineering services.
BioVascular is a clinical stage privately held biotechnology company developing “first in class“ products for platelet mediated cardiovascular diseases. BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conducting human clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft.
Merck Serono S.A. discovers, develops, manufactures, and commercializes prescription medicines focusing on various therapeutic areas that include oncology, immuno-oncology, immunology, multiple sclerosis, fertility, endocrinology, biosimilars, and neglected diseases. It develop treatments to help manage neurodegenerative diseases, such as multiple sclerosis; colorectal cancer; drugs to treat head and neck cancer; fertility drugs for every stage of the reproductive cycle.
Survac ApS focuses on the development of peptide based therapeutic cancer vaccines. It intends to offer the vaccine candidates for licensing and collaboration agreements.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.